Role of GPX4 in Ferroptosis and its Pharmacological Implication

Regulation and boundary between cosmetic, medical device and medicine In Europe, topical peptides fall under three distinct regulatory frameworks according to their claim and mechanism: Cosmetic (EC Regulation 1223/2009) Surface cutaneous action, beauty and hygiene claims No therapeutic claim authorised Product information file (PIF), safety evaluation Examples: Matrixyl, Argireline, Pal-GHK in anti-ageing serums Medical device (EU Regulation 2017/745) Main physical/mechanical action, medical claim Classes I, IIa, IIb, III according to risk CE marking mandatory, notified bodies for class IIa+ Example: GHK-Cu dressings for wound healing Medicine (Directive 2001/83/EC) Explicit therapeutic claim, pharmacological action MA mandatory (EMA or national agencies), phase I-III clinical trials Example: Afamelanotide for erythropoietic protoporphyria (MA 2014) This segmentation has direct implications for research : a molecule can change regulatory status according to its final formulation and claims

The relationships between this antioxidant and other aspects of your health are complex
The research confirms that GHK-Cu can effectively tighten loose skin and help make thin, fragile skin appear thicker and more resilient
About Press Copyright Contact us Creators Advertise Developers Impressum Cancel Memberships Terms Privacy Policy & Safety How YouTube works Test new features 2026 Google LLC Post from Real Talk Nutrition